. . "Humans and other mammals"@en . . . . . . . . "For the temporary relief of the signs and symptoms of allergic conjunctivitis."@en . . "1-(2-Ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1H-benzoimidazole"@en . . . . . . . . "Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis. [Wikipedia]"@en . . . . . . "Emedastine difumarate"@en . "Approximately 44% of the oral dose is recovered in the urine over 24 hours with only 3.6% of the dose excreted as parent drug. Two primary metabolites, 5- and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms."@en . . . . "Ophthalmic use of emedastine usually does not produce measurable plasma concentrations."@en . "The elimination half-life of oral emedastine in plasma is 3-4 hours."@en . . "Somnolence and malaise have been reported following daily oral administration."@en . . "1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole"@en . . " "@en . "87233-61-2"@en . "EMEDASTINE"@en . . . . . "approved"@en . . "Emedastine is a relatively selective, histamine H₁ antagonist. In vitro examinations of emedastine's affinity for histamine receptors demonstrate relative selectivity for the H₁ histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors."@en . "Emedastinum"@en . . . . . . . . . . . . "Emedastine"@en . . . . "1-[2-(Ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole"@en . "Emedastina"@en . . . .